Karyopharm Therapeutics

KPTIPhase 3

Karyopharm Therapeutics is an innovation-driven, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel cancer therapies. The company's core expertise lies in oral SINE (Selective Inhibitor of Nuclear Export) compounds that inhibit XPO1, a protein critical to cancer cell survival. With one approved product and multiple clinical-stage programs, Karyopharm is advancing treatments across various hematologic cancers and solid tumors, driven by a mission to improve the lives of patients with cancer.

Market Cap

$3.7B

Focus

Small Molecules

KPTI · Stock Price

USD 200.2540.50 (-16.82%)

Historical price data

AI Company Overview

Technology Platform

Oral Selective Inhibitor of Nuclear Export (SINE) technology targeting the XPO1 protein, a fundamental mechanism in oncogenesis that forces nuclear retention of tumor suppressor proteins and induces cancer cell death.

Pipeline Snapshot

87 drugs in pipeline, 7 in Phase 3

Drug	Indication	Stage
Selinexor + Selinexor + Ruxolitinib	Myelofibrosis	Phase 3
Selinexor + Matching placebo for selinexor	Endometrial Cancer	Phase 3
Selinexor + Elotuzumab + Pomalidomide + Dexamethasone Oral	Multiple Myeloma	Phase 3
Selinexor + Bortezomib + Dexamethasone	Multiple Myeloma	Phase 3
Selinexor + Matching Placebo for selinexor	Endometrial Cancer	Phase 3

Funding History

Total raised: $439M

PIPE$150MUndisclosedJun 15, 2020

IPO$120MUndisclosedNov 7, 2013

Series C$101MUndisclosedJul 15, 2013

Series B$48MUndisclosedJun 15, 2011

Opportunities

Growth opportunities include expanding the use of selinexor into earlier lines of therapy for multiple myeloma and DLBCL, successfully developing it for new solid tumor indications like endometrial cancer, and advancing next-generation SINE compounds.

The oral administration platform and novel mechanism provide a foundation for combination regimens and potential best-in-class profiles.

Risk Factors

Key risks include intense competition in core markets, potential clinical trial failures, reliance on the commercial success of a single product (selinexor), regulatory hurdles for new indications, and the need for potential future capital raises which could dilute shareholders.

Competitive Landscape

Karyopharm faces intense competition from numerous approved and investigational therapies in multiple myeloma and lymphoma, including proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and cell therapies. Its primary differentiation is its first-in-class oral XPO1 inhibitor mechanism, offering a novel treatment option and potential convenience advantage.